Serrapeptase is a proteolytic (protein destroying) enzyme from bacteria native to the digestive system of silkworms. It is the enzyme responsible for dissolving a silkworm’s cocoon.
Traditionally, serrapeptase has been used for its anti-inflammatory properties. Today, it is marketed as a joint health supplement.
Unfortunately, many studies on serrapeptase were poorly structured, with inadequate control groups. The most recent data suggests that serrapeptase is not a very effective supplement, as far as joint health and inflammation is concerned.
Though serrapeptase has been detected in plasma after supplementation, the standard oral dose for serrapeptase is low, which means very little is absorbed through the intestines. This may be one of the reasons serrapeptase is unreliable and not very effective.
Serrapeptase has been found to have the ability to liquefy mucus and reduce bacterial biofilms (reducing bacteria’s ability to stick to surfaces and each other). This means serrapeptase may be able to reduce phlegm buildup, nasal discharge, lung symptoms of cystic fibrosis and help other compounds fight bacteria. Additional research is needed to confirm these effects.
Serratiopeptidase, Serratia E-15, serralysin, serratiaprotease, Serratiopeptidase, Silk worm enzymes
The standard dose for serrapeptase is 10-60mg.
Serrapeptase should be supplemented on an empty stomach, which is 30 minutes before a meal or two hours after a meal, three times a day. Most studies use 10mg of serrapeptase taken every eight hours.
More human evidence is needed to determine the optimal dose of serrapeptase. 10mg of serrapeptase is equal to approximately 20,000 enzymatic units.
Serrapeptase appears to be more anti-bacterial than anything. It currently has potential usage for both augmenting antibiotics as well as reducing phlegm viscosity (some trials with serrapeptase in cystic fibrosis would be awesome).
It would be interesting to see studies just straight up superloading serrapeptase (to see if 'more is better' applies to this or not) and studies supplementing serrapeptase with things that augment paracellular transportation (Licorice bioactive glycyrrhetinic acid, in particular)
The Human Effect Matrix looks at human studies (excluding animal/petri-dish studies) to tell you what effect Serrapeptase has in your body, and how strong these effects are.
|Grade||Level of Evidence|
|A||Robust research conducted with repeated double blind clinical trials|
|B||Multiple studies where at least two are double-blind and placebo controlled|
|C||Single double blind study or multiple cohort studies|
|D||Uncontrolled or observational studies only|
Level of Evidence
||Magnitude of Effect Size
Appears to reduce swelling and inflammation following surgery or trauma, although to a lesser degree than corticosteroids. There is a lack of practical evidence for the ... show
When a decrease in inflammation occurs post surgery, there appears to be a concomitant reduction in pain; it tends to hover around a 1 point reduction on a VAS scale (scale ... show
See all 4 studies
A somewhat notable decrease in mostly the viscosity of mucus (elasticity is somewhat unreliably decreased), due to the mucolytic properties of serrapeptase. This may be ... show
A decrease in breast tenderness and soreness has been noted with serrapeptase treatment in one study.
See 2 studies
Related to the antiinflammatory effects, swelling and edema post surgery appear to be reduced.
|D||Symptoms of Carpal Tunnel||
A decrease in symptoms has been noted, but the study was not structurally a good one; requires replication
|D||Symptoms of Superficial Thrombophlebitis||
There appears to be a small decrease in symptoms, which is thought to be due to fibrinolytic properties of serrapeptase
Serrapeptase is a proteolytic enzyme touted for anti-inflammatory, anti-edemic, and analgesic properties and appears to be active following oral ingestion of an enteric coated capsule. Brand names for serrapeptase include Danzen, Serodase, Nemesulide, and Antiflazym.
Serrapeptase is produced from Serratia bacteria, found in the intestines of the silkworm (Bombyx mori) which sometimes leads to serrapeptase being referred to as 'silkworm enzymes'. Of the various species of serratia bacteria that can produce protease enzymes (indica, marcescens, plymuthica, and piscatorum). Serratia marcescens has a particular strain known as E15 (ATCC 13880) that has up to a threefold greater yeild and although marcescens in general is preferred for production of serrapeptase the E15 strain is favored.
Serrapeptase is not the only enzyme found from these bacteria, but is the major enzyme produced (three other larger but less common enzymes are also produced).
The serrapeptase enzyme has a molecular weight of 45,000-60,000Da (50.6kDa reported elsewhere) and is comprised of 470 amino acids in length; it is classified as a metalloprotease due to containing a Zinc molecule which helps catalyze its enzymatic activity. Although it shows maximal activity at 40°C and a pH of 9.0, it is fully inactivated at 55°C for 15min and possesses an isoelectric point of 5.3.
It's substrate specificity appears to be somewhat similar to that of thermolysin (produced from bacillus thermoproteolyticus), and the amino acid sequence is free of sulfur containing amino acids (cysteine and methionine).
Appears to be a rather large metalloprotease enzyme, which can be inactivated (rendered useless) by excess heat
Due to the supplement in question being an enzyme and destroyed in the acidic environment of the stomach, enteric coated capsules (resistant to acidity, and thus degrade in the intestines rather than the stomach) are used. Aquasomes (a carrier comprised of a nanocrystalline core coated with polyhydroxy oligomers) follow a similar idea, where it is stable for 2-6 hours in acidic medium (pH 1.2) and has a linear release rate in alkaline medium (pH 7.4).
Serrapeptase is destroyed in the acidic environment of the stomach, and as such would require enteric encapsulation in order to retain the bioactivity
Despite being a large protein structure, serrapeptase has been found to be absorbed in the rat intestine following oral administration, although the large structure and possible degradation in the intestines has been cited to possible reduce the bioavailability of serrapeptase (enzymes are readily degraded by drastic changes in pH and large protein structures may not be absorbed well).
Serrapeptase alone appears to have low permeability in a Caco-2 model of intestinal permeability (–7.72+/- 0.51cm/s) which appears to slightly improved with liposomal delivery systems (Phosphatidylcholine up to -7.47+/-0.36cm/s and 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine up to -6.5+/-0.35cm/s). It was noted that this may underestimate the absorption of serrapeptase a bit, as Caco-2 cells have tighter gap junctions than do in vivo conditions (and thus less paracellular transport).
The enhanced absorption of serrapeptase with liposomes is thought to due to liposomes increasing paracellular (between cells) transport of molecules and serrapeptase being too large for transport-mediated absorption (and thus likely mediated by paracellular transport).
Serrapeptase, surprisingly, is absorbed through the intestinal wall similar to Bromelain and appears to retain its enzymatic activity. It appears to be absorbed paracellularly (between cells), but does not appear to be well absorbed although it is enhanced by liposomesSerrapeptase has been thought to be used topically, although isopropyl myristate (IPM) or dimethyl sulfoxide (DMSO) are required to enhance skin absorption (due to serrapeptase being a large enzyme structure) and were required at higher than acceptable concentrations according to the authors. In a rat anti-edema test, a topical gel (Monegyl 0100 at 10%, PEG 400 at 40%, Propylene glycol at 10%, 1% serrapeptase, and PEG 4000 added until mixture congeals) was comparable in efficacy to a diclofenac gel suggesting some bioactivity.
Other delivery methods that have been reported are a glyceryl monooleate based system.
There is limited evidence that serrapeptase can be bioactive topically, which needs to be re-evaluated and mechanisms investigated more (as it is quite illogical for a large protein structure to be absorbed via the skin)
It has been detected in serum following an oral dose of 100mg/kg (rats) to 0.87+/-0.41ng/mL, and in lymph it had higher concentrations of 43+/-42ng/mL at a Tmax of 15-30 minutes. A minimum dose of 30mg/kg was required to find any detectable concentration in plasma, yet only 1mg/kg for a level in lymph tissue.
In rats it appears to travel through the blood bound to plasma protease inhibitor alpha-1 macroglobulin (α1M) in a 1:1 ratio; this has been noted to reduce the enzymatic activity to about 20% of its inhernet value, but a value still appears to be present.
Serrapeptase has been found to be distributed to sites of inflammation in the rat (careegnaan induced) to a concentration higher than serum.
Pain has been noted to be reduced on days 1-5 after jaw surgery with 15mg serrapeptase relative to placebo (study confounded with 1000mg paracetamol in both groups) but no significant difference on day 7, with a 3 point reduction on day 1 (VAS scale; a rating from 0-10) and a 1 point difference afterwards.
A study in breast pain (engorgement and swelling) noted that 30mg of serrapeptase for 3 days was able to increase the amount of response (persons who reported pain reduction) from 60% to 85.7% and increase reported 'marked improvements' in pain from 2.9% in placebo to 22.9%.
It is claimed that the enzymatic activity of serrapeptase (appears to be somewhat preserved following oral ingestion) is able to hydrolyze bradykinin, histamine and serotonin which are responsible for edemic processes.
10mg of serrapeptase thrice a day the day prior to and of surgery (maxillary sinus antrotomy) as well as for 5 subsequent days (7 days in total), relative to placebo, was able to significantly reduce jaw swelling at all measured time points.
In patients undergoing removal of third molars given paracetamol (1000mg) paired with serrapeptase (15mg daily, 5mg taken every 8 hours for 7 days) or placebo, there was a significantly reduction in cheek swelling on all measured days except immediately after surgery while pain followed the opposite trend (significantly more effective than placebo days 1-5 after surgery, but not day 7); interincisal difference was not affected. Other studies on third molar surgeries noted that either serrapeptase is ineffective in reducing inflammation or the standard 30mg dose is effective, but to a lesser degree than 3mg dexamethasone (1mg thrice daily).
The research looking at jaw inflammation appears to support the usage of serrapeptase, but aside from the studies being limited it appears to be less effective than the reference drug (dexamethasone)
One study in carpal tunnel syndrome given an initial course of nimesulide and then followed up with 10mg serrapeptase twice daily (20mg daily) for 6 weeks noted a 65% response rate for 'significant improvement' but did not have a placebo group for comparison.
The evidence to support a role in carpal tunnel syndrome is, methodologically speaking, quite weak
In rats, the anti-inflammatory effects of serrapeptase at 10-20mg/kg was compaed against 0.5mg/kg diclofenac (for both an acute inflammation study over 8 hours and a chronic inflammation study over 9 days) noted that all groups were comparable in reducing paw edema acutely (43.18-54.55% suppression of paw edema) but there appeared to be dose-dependence for chronic inflammation where 10mg/kg serrapeptase underperformed diclofenac (40% inhibition of paw edema relative to 72%) while 20mg/kg was comparable (68% relative to 72%).
Anti-inflammatory effects appear to exist in rats following oral ingestion
A meta-analysis of 14 trials noted that the six positive trials included (five can be found online) were fairly low quality, with three trials not disclosed the given dose and one not compared to any control or placebo group; the final two studies that were positive were in treating jaw swelling after maxillary sinus antrotomy surgery and for reducing breast engorgement ('marked improvement' was 22.9% with serrapeptase, 2.9% with placebo); both studies used 30mg daily in three doses of 10mg for 7-14 days.
The studies that support the efficacy of serrapeptase appear to be low in quality
In staphylococci bacteria (epidermidis and aureus populating human skin and mucus membranes) are bacteria that can produce protein-dependent biofilms and protease enzymes are a class of molecules which are sometimes used to disperase these biofilms. At 50U/mL (2.5mcg/mL), serrapeptase was able to inhibit biofilm production of all tested strains (aureus strains ATCC 6538P, 25923, 35984, and 12598 as well as epidermis strains XX-17 and O-47). Efficacy has also been noted against 5 strains of Pseudomonas aeruginosa and Listeria monocytogenes.
In a comparative analysis, serrapeptase was more potent than other tested proteases (Clostridiopeptidase A, fibrinolysin, and streptokinase).
For bacteria that create protein-dependent biofilms, it appears that serrapeptase may have an inhibitory effect on biofilm production
Biofilms are used by bacteria to, aside from adherence to cells, to prevent infiltration of the bacteria cell from antibacterial agents and in vitro serrapeptase (100U/mL; 5mcg/mL) has been found to augment the anti-bacterial properties of ofloxacin by approximately halving the minimum inhibitory concentration.
In vitro, serrapeptase has been found to augment antibacterials which is thought to be from reducing biofilm production (which then enhances the ability of the antibacterial agent to target the bacteria since it is removing the bacterial defenses). These have not yet been noted in a living model
Serrapeptase is known as a mucus liquifying agent and 30mg of serrapeptase daily for 4 weeks in persons with chronic airway diseases has been noted to significantly decrease sputum weight and neutrophil count as well as its viscosity and elasticity; a significant decrease in the frequency of coughing and expectoration was also noted.
Elsewhere, serrapeptase has been noted to reduce dynamic viscosity of nasal secretion with affecting the elastic modulus and this effect (a reduction in viscosity but not elasticity) has been noted elsewhere following oral ingestion of 30mg serrapeptase daily for 4 weeks. Other studies, however, either note a decrease in both viscosity and elasticity (lung sputum) or a decrease in viscoelasticity. While the decrease in viscosity appears to be reliable, the elasticity is not as much.
Appears to alter mucus secretions of the body. Although there is not an ample amount of evidence for this, it may be of use to persons with chronically stuffed noses (sinusitis) and for lung symptoms of cystic fibrosis (currently untested)
The biofilm reducing properties of serrapeptase have also been noted to be of use in rats given a surgery with risk for infection afterwards (by biofilm producing bacteria), where the occurrence rates of bacterial growth on the surgical site of 63.2% (control) was reduced with antibiotic treatment (37.5%) and synergistically reduced with the addition of serrapeptase to antibiotics (5.6%).
Serrapeptase appears to be synergistic with antibiotic drugs and molecules. Serrapeptase has the ability to reduce the biofilms produced by select bacteria and these biofilms can impair the ability of antibiotics to destroy a bacteria.
In vitro, serrapeptase (100U/mL; 5mcg/mL) has been found to augment the anti-bacterial properties of ofloxacin by approximately halving the minimum inhibitory concentration and in a rat model of surgery where the occurrence of bacterial infection in control (63.2%) was reduced to 37.5% with antibiotics but down to 5.6% with the combination treatment of antibiotics and serrapeptase.
Elsewhere in rabbits, the plasma concentrations of Cefotiam appear to be increased following coingestion of serrapeptase, while only increasing tissue concentrations in the rabbit model of pneumonitis (no effect in pleuritis) and has been noted to increae gingival concentrations of four antibiotic drugs (Ciclacillin, ampicillin, cephalexin, and minocycline) in rats given 20mg/kg serrapeptase.
Appears to augment antibiotic efficacy by reducing the inhibitory effects of bacterial biofilms
One study assessing the interactions of injections of proteolytic enzymes (Serrapeptase, chymotrypsin, or trypsin) and aspirin noted that all enzymes were synergistic with aspirin in acute and subacute inflammatory tests in rats; this study also noted that 90-270µg/kg serrapeptase was equivalent to 200mg/kg (oral ingestion) and was equivalent to trypsin (288-576µg/kg) and chymotrypsin (18-36mg/kg) in potency.
A systemic review on serrapeptase has noted that there are limited adverse drug reactions reported, but they tend to be related to skin conditions (such as erythema or dermatosis) and both muscle and joint pain; there appear to be some reported coagulation problems.
Commonly said to be safe (although there really isn't any robust toxicological data on this claim) and has been linked to sporadic side-effects related to joints and the skin. Occurrence rates are not known, but they seem rare
(Common phrases used by users for this page include lethal dose of serratiopeptidase, serrapeptase, oral dose of serratiopeptidase, serodase R uses and side effects, http://examine.com/supplements/Serrapeptase/, serrapeptase dose)